Growth in the domestic pharma market dipped in September over the previous month, but was still nearly double digit at 9.6%.
The industry had posted a robust growth of 16.5% in August this year. Ironically, a meagre growth of 7% in anti-infectives — seems to have pulled down the industry’s growth during the month.
This was also reflected in performance of top anti-infective brands, with the exception of Augmentin and Ceftum (Glaxo) which grew by 16.7% and 43.4% respectively over the corresponding period previous year. Others reported a modest show — Taxim (Alkem, -5.3%), Zifi (FDC, 6.5%), Mox (Ranbaxy, 7.9%), Monocef (Aristo, 1.7%), Sporidex (Ranbaxy, -12.9%) and Novamox (Cipla, -0.9%).
The largest therapeutic segment with an industry share of 25%, gastro-intestinal and metabolic diseases grew by a healthy 14%, according to market consultancy ORG-IMS.
Zydus Cadila executive director Ganesh Nayak said the performance of pharma industry during September is on expected lines. With low monsoons this year, the off take in anti-infectives has been impacted which has brought down the overall industry growth rate while the other segments, that are non-seasonal in nature, have continued to grow and have been able to balance the downtrend in anti-infective segment. Hence this dip in growth rate is a monthly aberration which will get corrected on its own in the coming months.
Most top-ranking companies including Sun Pharma, Glaxo, Zydus Cadila and Piramal Healthcare posted a healthy growth during the month, in some cases even exceeding industry growth, industry sources said. Sun Pharma led the pack with 18.4% growth, followed by Ahmedabad-based Zydus Cadila which grew by 16.7%. Glaxo, the third largest company (in terms of market share) also recorded a healthy growth of 16%, while Piramal Healthcare posted a growth of 14.3% followed by Mankind which recorded a growth of 13.4%.
Among the top 10 companies, Cipla (5.1%) and Aristo (4.8%) underperformed as against the industry.
There were no changes observed in the ranking of top 10 companies during the month with Cipla at the top spot, followed by Ranbaxy and GSK. The remaining slots were occupied by Piramal Healthcare which was ranked fourth, followed by Zydus Cadila at the fifth position.
Among the top 20 companies, top gainers in September (as against August ‘09) were Sanofi Aventis, Emcure and Intas Pharma, who have gained one rank each and moved up to rank 15, 16 and 18 respectively.
Amongst drugs, cough syrup Phensedyl Cough occupied the topmost position leaping eight ranks to move to first slot, while another cough syrup Corex and pain killer drug Voveran were ranked at the second and third slot. Other top gainers included Augmentin, Cifran and Omez who have gained three ranks each and moved up to rank 5th, 16th and 21st slots respectively.